Cardiol Therapeutics Inc. (NASDAQ:CRDL) Shares Bought by Tejara Capital Ltd

Tejara Capital Ltd lifted its position in shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) by 75.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,115,437 shares of the company's stock after purchasing an additional 1,344,167 shares during the quarter. Cardiol Therapeutics accounts for approximately 2.6% of Tejara Capital Ltd's portfolio, making the stock its 14th largest holding. Tejara Capital Ltd owned 3.77% of Cardiol Therapeutics worth $3,988,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Atria Investments Inc purchased a new position in shares of Cardiol Therapeutics during the 4th quarter valued at approximately $174,000. Jones Financial Companies Lllp purchased a new position in Cardiol Therapeutics in the 4th quarter valued at $25,000. Lion Street Advisors LLC lifted its holdings in Cardiol Therapeutics by 12.6% in the 4th quarter. Lion Street Advisors LLC now owns 307,666 shares of the company's stock valued at $396,000 after purchasing an additional 34,385 shares in the last quarter. Jane Street Group LLC purchased a new position in Cardiol Therapeutics in the 3rd quarter valued at $29,000. Finally, Townsquare Capital LLC purchased a new position in Cardiol Therapeutics in the 3rd quarter valued at $27,000. Institutional investors and hedge funds own 12.49% of the company's stock.

Cardiol Therapeutics Trading Up 5.4 %

Shares of NASDAQ:CRDL traded up $0.06 during midday trading on Wednesday, reaching $1.18. 203,752 shares of the company's stock were exchanged, compared to its average volume of 390,253. The firm's 50 day simple moving average is $1.25 and its two-hundred day simple moving average is $1.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.49 and a quick ratio of 2.49. The stock has a market cap of $97.48 million, a price-to-earnings ratio of -3.03 and a beta of 0.95. Cardiol Therapeutics Inc. has a fifty-two week low of $1.02 and a fifty-two week high of $3.12.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. RODMAN&RENSHAW upgraded Cardiol Therapeutics to a "strong-buy" rating in a report on Tuesday, January 28th. HC Wainwright reiterated a "buy" rating and set a $9.00 price target on shares of Cardiol Therapeutics in a report on Monday, February 24th. Finally, Rodman & Renshaw initiated coverage on Cardiol Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $7.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $8.40.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.